Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2026 • ACR Convergence 2023
Developing a Guided Joint Self-Exam for Rheumatoid Arthritis Patients to Use in Telehealth-Delivered Care
Kelly Gavigan¹, David Curtis², Jeffrey Curtis³, W. Benjamin Nowell⁴, Danielle Ali⁵, Neelkamal Soares⁶, John Cush⁷, Rebecca Grainger⁸, Manas Jinka⁹, Sandeep Sodhi¹⁰, Natalie Fortune⁹ and Swamy Venuturupalli⁹, ¹Global Healthy Living Foundation, Upper Nyack, NY, ²Global Healthy Living Foundation, San Francisco, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Global Healthy Living Foundation, Upper Nayack, NY, ⁶Western Mich Univ Homer Stryker MD Sch of Medicine, Kalamazoo, MI, ⁷University of Texas Southwestern Medical School, Dallas, TX, ⁸University of Otago, Wellington, New Zealand, ⁹Attune Health, Beverly Hills, CA, ¹⁰Illumination Health, Hoover, AL
Background/Purpose: Telehealth services and, increasingly, remote therapeutic monitoring, can be used to enable the continuum of clinical care in out-of-office settings. This remotely provided care…
Abstract Number: 2107 • ACR Convergence 2023
Social Determinants of Health and Clinical Outcomes in Rheumatoid Arthritis: A Single Center Study
Nicholas Wiemer¹, Yue Yin² and Tarun Sharma¹, ¹Allegheny Health Network, Pittsburgh, PA, ²Allegheny Health Network Singer Research Institute, Pittsburgh, PA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic and potentially debilitating disease.Social determinants, including smoking and depression, have been shown to be linked to worse clinical…
Abstract Number: 2123 • ACR Convergence 2023
Dose Trabecular Bone Score (TBS) Add Predictive Value to Fracture Risk Assessment (FRAX) in Rheumatoid Arthritis?
Jia-Feng Chen¹, Tien-Tsai Cheng² and Hong-Yo Kang³, ¹Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, ²Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, Kaohsiung, Taiwan, ³Graduate Institute of Clinical Medical Sciences, Chang Gung University, College of Medicine, Kaohsiung, Taiwan
Background/Purpose: Trabecular bone score (TBS) of lumbar spine is a dual X-ray densitometry (DXA)-based tool to evaluate bone microarchitecture, providing information on bone quality in…
Abstract Number: 2139 • ACR Convergence 2023
Associations of Adipocytokines with Cancer Incidence in a Prospective Rheumatoid Arthritis Cohort
Namrata Singh¹, Aaron Baraff², K Wysham³, Punyasha Roul⁴, Grant Cannon⁵, Brian Sauer⁶, Geoffrey Thiele⁴, Bryant England⁴, Ted R Mikuls⁷ and Joshua Baker⁸, ¹University of Washington, Bellevue, WA, ²VA Puget Sound Seattle, Seattle, WA, ³VA Puget Sound/University of Washington, Seattle, WA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁶Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: A prior study suggested a higher risk of cancer mortality in patients with rheumatoid arthritis (RA) with higher levels of circulating leptin, an adipocytokine…
Abstract Number: 2155 • ACR Convergence 2023
The Impact of Filgotinib on Disease Activity Outcomes with Concomitant Pain Control in the Phase 3 FINCH Studies
Peter C. Taylor¹, Arthur Kavanaugh², Peter Nash³, Janet Pope⁴, Georg Pongratz⁵, Bruno Fautrel⁶, Rieke Alten⁷, Ken Hasegawa⁸, Shangbang Rao⁹, Dick de Vries¹⁰, Pieter-Jan Stiers¹¹, Chris Watson¹² and René Westhovens¹³, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ³School of Medicine, Griffith University, Brisbane, Australia, ⁴University of Western Ontario, London, ON, Canada, ⁵Faculty of Medicine, Regensburg University, Regensburg, Germany, Regensburg, Germany, ⁶Sorbonne Université APHP, Paris, France, ⁷Department of Internal Medicine and Rheumatology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany, ⁸Global Medical Affairs Research, Gilead Sciences, Inc., Foster City, CA, ⁹Biostatistics, Gilead Sciences, Inc., Foster City, CA, ¹⁰Research and Development, Clinical Research, Galapagos BV, Leiden, Netherlands, ¹¹Biostatistics, Galapagos NV, Mechelen, Belgium, ¹²Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, ¹³Department of Rheumatology, KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) often experience substantial pain despite treatment, and consider pain control an important treatment outcome. This post hoc analysis…
Abstract Number: 2172 • ACR Convergence 2023
Subcutaneus vs Intravenous Abatacept in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 509 Patients
Ana Serrano-Combarro¹, Belén Atienza-Mateo², libe Ibarrola-Paino³, Ivette Casafont-Sole⁴, Rafael Benito Melero-Gonzalez⁵, Alba Perez Linaza⁶, Santos Castañeda⁷, Rafaela Ortega Castro⁸, Natalia Mena Vazquez⁹, Nuria Vegas Revenga¹⁰, Lucia Cristina Dominguez Casas¹¹, Elena Cañadillas-Sanchez¹², Miriam Retuerto-Guerrero¹³, Lorena Perez-Albadalejo¹⁴, Ruben Lopez-Sanchez¹⁵, MARIA GUADALUPE MANZANO CANABAL¹⁶, Anahy Maria Brandy-Garcia¹⁷, Patricia Lopez-Viejo¹⁸, Gema Bonilla¹⁹, Olga Maiz-Alonso²⁰, Carmen carrasco-Cubero²¹, Marta Garijo Bufort²², Mireia Moreno²³, Ana Urruticoechea²⁴, Sergio Ordonez-Palau²⁵, Carmen Gonzalez-Montagut Gomez²⁶, andrea Garcia-Valle²⁷, Marta López²⁸, Fernando Lozano²⁹, Tomás Vazquez-Rodriguez³⁰, Maria Martin-Lopez³¹, Juan Maria Blanco-Madrigal³², Cristina Arciniega³³, Ignacio Brana Abascal³⁴, Jesus Loarce-Martos³⁵, Emilio Giner-Serret³⁶, Virginia Ruiz-Esquide³⁷, Clara ventin-Rodriguez³⁸, Marina Rodriguez-lopez³⁹, Pablo Andujar-Brazal⁴⁰, Julia Fernandez-Melon⁴¹, Lilian Maria Lopez⁴², Antonio Juan Mas⁴³, carlos Fernandez-Diaz⁴⁴, Javier Loricera⁴⁵, Diego Ferrer⁴⁶ and Ricardo Blanco⁴⁷, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Universitario de Navarra, Pamplona, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵CHU Vigo, O Carballino, Spain, ⁶SERV. REUMATOLOGIA, Cadiz, Spain, ⁷Hospital Universitario de la Princesa, Madrid, Spain, ⁸Hospital Reina Sofía, Cordoba, Spain, ⁹IBIMA, Málaga, Spain, ¹⁰Hospital Galdakao- Usansolo, Galdakao, Spain, ¹¹Hospital Universtario San Agustin, Oviedo, Spain, ¹²Department of Rheumatology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹³Rheumatology, Hospital Universitario de León, León, Spain, ¹⁴Division of Rheumatology, Hospital Universitario de Jaén, Jaén, Spain, ¹⁵Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain, ¹⁶CAZA, Salamanca, Spain, ¹⁷Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁸Division of Rheumatology, Hospital Severo Ochoa, Leganéz, Spain, ¹⁹Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁰University Hospital Donostia, San Sebastian, Spain, ²¹Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, ²²Hospital de Sagunto, Valencia, Spain, ²³Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ²⁴Hospital Can Misses, Ibiza, Spain, ²⁵H. Arnau de Vilanova, Lleida, Spain, ²⁶H. Clínico Universitario de Valladolid, Valladolid, Spain, ²⁷Division of Rheumatology, Complejo Asistencial Universitario de Palencia, Palencia, Spain, ²⁸Hospital Universitario Arava, Pamplona, Spain, ²⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ³⁰Rheumatology, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain, ³¹Hospital 12 de Octubre, Madrid, Spain, ³²Division of Rheumatology, H. Universitario de Basurto, Bilbao, Spain, ³³Hospital de Mérida, Mérida, Spain, ³⁴Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ³⁵Ramón y Cajal University Hospital, Madrid, Spain, ³⁶Hospital Royo Villanova, Teruel, Spain, ³⁷Hospital Clinic, Rheumatology, Barcelona, Spain, ³⁸Division of Rheumatology, Hospital Universitario de A Coruña, A Coruña, Spain, ³⁹Division of Rheumatology, Hospital Clínico Universitario de Santiago, La Coruna, Spain, ⁴⁰Division of Rheumatology, Hospital Universitario Doctor Peset, Valencia, Spain, ⁴¹Division of Rheumatology, Hospital Universitario Son Espases, Palma de Mallorca, Spain, ⁴²Division of Rheumatology, Hospital Universitario Son Llàtzer, Mallorca, Spain, ⁴³Son Llazter University Hospital, Palma, Spain, ⁴⁴Division of Rheumatology, Hospital Universitario Reina Sofía, Murcia, Spain, ⁴⁵Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴⁶Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴⁷Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated efficacy in RA-ILD. Clinical trials have shown…
Abstract Number: 2452 • ACR Convergence 2023
Assessment of Association Between Hydroxychloroquine Use and Toxic Retinopathy, Overall and by Indication, in a Large Cohort of Rheumatology Patients Within the US Department of Defense Military Healthcare System
Rachel Robbins¹, Toni Rush² and Jess Edison³, ¹Walter Reed National Military Medical Center, Germantown, MD, ²Health Research Tx, Pace, FL, ³Uniformed Services University of the Health Sciences / National Capital Consortium- Walter Reed Bethesda, Bethesda, MD
Background/Purpose: While generally believed to be a safe, well-established treatment, hydroxychloroquine (HCQ) use is associated with irreversible retinal toxicity requiring regular monitoring. The objective of…
Abstract Number: 2542 • ACR Convergence 2023
Impact of Concomitant Methotrexate on Disease Activity After Tapering Abatacept in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study
Jun Won Park¹, Min Jung Kim², Hyoun-Ah Kim³, Jin Hyun Kim⁴ and Kichul Shin⁵, ¹Seoul National University Hospital, Seoul, South Korea, ²Seoul Metropolitan Government Boramae Medical center, Dongjak-gu, Seoul, South Korea, ³Ajou University School of Medicine, Suwon, South Korea, ⁴Chungnam National University College of Medicine, Daejeon, South Korea, ⁵Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, South Korea
Background/Purpose: Recent randomized-controlled studies have suggested that tapering bDMARDs and/or csDMARDs after achieving sustained remission in patients with rheumatoid arthritis (RA) can be considered. However,…
Abstract Number: 020 • 2023 Pediatric Rheumatology Symposium
Generation of Human Resident Memory T Cells in 3D Synovial Organoid Model
Margaret Chang¹, Maryrose Hahn¹, Brian Wauford¹, Rachel Blaustein², Kevin Wei² and Peter Nigrovic¹, ¹Boston Children's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Most rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) patients experience episodic arthritis flares and require life-long medications to control their disease. We observed…
Abstract Number: 118 • 2023 Pediatric Rheumatology Symposium
Serum Hepatocyte Growth Factor in Children with Juvenile Idiopathic Arthritis
Natalia Shevchenko and Olga Pavlova, V. N. Karazin Kharkiv National University, Kharkiv, Ukraine
Background/Purpose: Only limited data are available on the risk of liver fibrosis in patients with rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA) on long-term…
Abstract Number: 136 • 2023 Pediatric Rheumatology Symposium
Incidence and Disease Burden of Juvenile Idiopathic Arthritis and Rheumatoid Arthritis After Non-Pharmaceutical Interventions in the COVID-19 Era: A Nationwide Observational Study in Korea
Je Hee Shin¹, Jung Yoon Pyo², Minkyung Han³, Myeongjee Lee³, Sung Min Lim¹, Jee Yeon Baek¹, Ji Young Lee¹, Ji-Man Kang¹, InKyung Jung³ and Jong Gyun Ahn¹, ¹Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, ²Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea, ³Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea
Background/Purpose: Several countries have implemented non-pharmaceutical interventions (NPIs) against the coronavirus disease 2019 (COVID-19) pandemic. We investigated the impact of NPIs on the incidence of…
Abstract Number: L03 • ACR Convergence 2022
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis
Jay Tuttle¹, Edit Drescher², Jesus Abraham Simón-Campos³, Paul Emery⁴, Maria Greenwald⁵, Alan Kivitz⁶, Hyungmin Rha¹, Pia Yachi¹, Christina Kiley¹ and Ajay Nirula⁷, ¹Eli Lilly and Company, Indianapolis, IN, ²Csolnoky Ferenc Hospital, Veszprém, Hungary, ³Köhler & Milstein Research/Hospital Agustín O'Horán, Merida, Yucatan, Mexico, ⁴University of Leeds, Leeds, United Kingdom, ⁵Desert Medical Advances, Palm Desert, CA, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷Eli Lilly, San Diego, CA
Background/Purpose: Peresolimab is a humanized immunoglobulin G1 monoclonal antibody that stimulates human programmed cell death protein 1 (PD-1). We hypothesized that peresolimab binding to PD-1,…
Abstract Number: L06 • ACR Convergence 2022
Risk of Extended Major Adverse Cardiovascular Event Endpoints with Tofacitinib vs TNF Inhibitors in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of a Phase 3b/4 Randomized Safety Study
Maya H. Buch¹, Deepak L. Bhatt², Christina Charles-Schoeman³, Jon T. Giles⁴, Ted R. Mikuls⁵, Gary Koch⁶, Steven Ytterberg⁷, Edward Nagy⁸, Hyejin Jo⁹, Kenneth Kwok⁹, Carol A. Connell¹⁰, Karim R. Masri¹¹ and Arne Yndestad¹², ¹Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ²Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³Division of Rheumatology, Department of Medicine, University of California, Los Angeles, CA, ⁴Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ⁵Division of Rheumatology, University of Nebraska Medical Center and VA Nebraska-Western Iowa Health Care System, Omaha, NE, ⁶Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁷Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁸Pfizer Ltd, Tadworth, Surrey, United Kingdom, ⁹Pfizer Inc, New York, NY, ¹⁰Pfizer Inc, Groton, CT, ¹¹Pfizer Inc, Collegeville, PA, ¹²Pfizer Inc, Oslo, Norway
Background/Purpose: ORAL Surveillance (NCT02092467; a post-authorization safety study of tofacitinib 5 and 10 mg twice daily [BID] vs TNF inhibitors [TNFi]) found higher risk of…
Abstract Number: 0047 • ACR Convergence 2022
Cenerimod, a Novel Selective S1P1 Receptor Modulator, Prevents or Attenuates Joint Inflammation in Several Preclinical Models of Rheumatoid Arthritis
Thomas Hoyler, Jeremy Scherer, Maxime Bulle, Conrad Wyss, Sylvie Froidevaux and Marianne Martinic, Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland
Background/Purpose: Targeting the sphingosine-1-phosphate (S1P) pathway has become an attractive target for therapeutic intervention in autoimmune diseases due to its selective impact on the migration…
Abstract Number: 0086 • ACR Convergence 2022
Patient and Provider Perspectives on Barriers to Communication and Care of Latinx Patients with Lupus and Rheumatoid Arthritis
Monica Crespo Bosque¹, Pablo Weilg Espejo² and Candace Feldman³, ¹Boston University, Boston, MA, ²Boston Medical Center, Chelsea, MA, ³Brigham and Women's Hospital, Boston, MA
Background/Purpose: Latinx patients, a heterogenous population with a range of experiences including migration, language, and race, experience a disproportionate burden of adverse outcomes from systemic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].